AbbVie (ABBV) hikes 2024 earnings guidance as Q1 beat estimates, shares up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbvie (ABBV) PT Lowered to $187 at Barclays
April 29, 2024 5:22 AM EDTBarclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.
The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."
... MoreAbbVie (ABBV) Tops Q1 EPS by 4c, Raises Guidance
April 26, 2024 7:36 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.31, $0.04 better than the analyst estimate of $2.27. Revenue for the quarter came in at $12.31 billion versus the consensus estimate of $11.93 billion.
GUIDANCE:
AbbVie sees FY2024 EPS of $11.13-$11.33, versus the consensus of $11.10.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More